Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthmaLANIER, Bob; BRIDGES, Tracy; KULUS, Marek et al.Journal of allergy and clinical immunology. 2009, Vol 124, Num 6, pp 1210-1216, issn 0091-6749, 7 p.Article

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisCHERVINSKY, Paul; CASALE, Thomas; TOWNLEY, Robert et al.Annals of allergy, asthma, & immunology. 2003, Vol 91, Num 2, pp 160-167, issn 1081-1206, 8 p.Article

Omalizumab improves asthma-related quality of life in patients with severe allergic asthmaFINN, Albert; GROSS, Gary; VAN BAVEL, Julius et al.Journal of allergy and clinical immunology. 2003, Vol 111, Num 2, pp 278-284, issn 0091-6749, 7 p.Article

Effect of Omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trialCASALE, Thomas B; CONDEMI, John; FIEK, Robert et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 23, pp 2956-2967, issn 0098-7484Article

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthmaDJUKANOVIC, Ratko; WILSON, Susan J; HOLGATE, Stephen T et al.American journal of respiratory and critical care medicine. 2004, Vol 170, Num 6, pp 583-593, issn 1073-449X, 11 p.Article

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaBUSSE, William; CORREN, Jonathan; LANIER, Bobby Quentin et al.Journal of allergy and clinical immunology. 2001, Vol 108, Num 2, pp 184-190, issn 0091-6749Article